Custom Solutions for Down Syndrome Animal Model Development

Download

Down syndrome (Trisomy 21) is the most common genetic cause of intellectual disability worldwide, caused by the presence of an extra full or partial copy of human chromosome 21. This genetic dosage imbalance affects multiple biological systems, leading to a complex spectrum of clinical manifestations including severe cognitive impairment, early-onset Alzheimer’s disease pathology, congenital heart defects, and metabolic abnormalities. To unravel these multifaceted disease mechanisms and evaluate potential therapeutic interventions, high-fidelity animal models that closely recapitulate human chromosomal alterations and clinical phenotypes are indispensable.

At Protheragen , we offer comprehensive preclinical research services spanning diagnostics development, therapeutic discovery, disease model development, and rigorous preclinical evaluation. Leveraging our advanced genetic engineering platforms, we specialize in custom Down syndrome animal model development. We provide custom-designed, genetically modified animal models tailored to mimic the precise genetics and phenotypical traits of Down syndrome, enabling drug discovery teams to generate actionable, high-quality translational data.

Overview of Down Syndrome Animal Models

Down syndrome animal models are sophisticated biological tools created to simulate the genetic trisomy and gene overexpression characteristic of human Trisomy 21. Because human chromosome 21 (HSA21) shares syntenic orthology with regions on mouse chromosomes 16, 10, and 17, researchers utilize transgenic, transchromosomic, and chromosome engineering techniques to create rodent models carrying partial or complete trisomies. These models faithfully mirror human disease features—ranging from structural synaptic deficits and neuroinflammation to cognitive decline and cardiovascular malformations—making them essential platforms for understanding genotype-phenotype relationships and translating bench discoveries into clinical therapies.

Applications of Down Syndrome Animal Models

Down syndrome animal models serve as versatile experimental systems across multiple stages of translational research, providing valuable insights into disease etiology and drug efficacy. Key applications include:

Workflow for Down Syndrome Animal Model Development

To ensure high reproducibility, scientific rigor, and precision in model construction, Protheragen follows a standardized, step-by-step development workflow:

• Target Identification & Strategy Design: Defining specific genetic modifications (e.g., chromosome translocation, gene duplication, or transchromosome insertion) based on project objectives.
• Genetic Vector Engineering & Cell Editing: Utilizing CRISPR/Cas9 or Cre/loxP-mediated chromosome engineering in embryonic stem (ES) cells or zygotes to construct target genetic duplications.
• Blastocyst Microinjection & Chimera Generation: Injecting verified modified ES cells into host blastocysts, followed by embryo transfer to surrogate mothers to generate chimeric founder lines.
• Breeding & Line Establishment: Crossing founder animals with appropriate background strains to establish stable, heterozygous or trisomic breeding colonies.
• Genotypic & Phenotypic Validation: Confirming gene copy number variations via qPCR, FISH, karyotyping, and conducting baseline functional assessments (behavioral, histological, and molecular analyses).

Available Down Syndrome Animal Models

Integrated Preclinical Research Services for Down Syndrome

Beyond custom animal model generation, Protheragen delivers comprehensive, end-to-end preclinical research services designed to accelerate therapeutic candidates from early discovery to IND-enabling stages:

Case Study-Ts65Dn Mouse Model

Using Cre/loxP chromosome engineering in mouse ES cells, Protheragen established the Ts65Dn mouse model carrying the Ts(17¹⁶)65Dn translocated chromosome, which duplicates a 5.4 Mb Mmu16 segment (~92 Hsa21 orthologs) onto Mmu17. Due to male infertility, the line is maintained by breeding Ts65Dn females with B6C3F1 males and genotyped via qPCR or FISH for triplicated genes (e.g., Dyrk1a, App). In the novel object recognition task (NORT), 4-month-old Ts65Dn males showed marked memory deficits, which were fully restored to wild-type levels by candidate drug treatment (0.5 mg/kg/day). By 10 months, chronic administration sustained NOR memory improvements in both sexes without tolerance, demonstrating durable efficacy across ages and sexes.

Fig 1. Novel object recognition test (NORT) discrimination index in male (A, B) and female (C) WT and Ts65Dn mice treated with Vehicle or Candidate (0.5 mg/kg/day). * P ˂ 0.05, ** P ˂ 0.01 (genotype effect); ^# P ˂ 0.05, ^## P ˂ 0.01, ^### P ˂ 0.001 (treatment effect).

Histopathological and neuroinflammatory analyses revealed that compared to wild-type mice, 10-month-old Ts65Dn mice showed significant soma enlargement of hippocampal microglia, alongside markedly elevated plasma levels of pro-inflammatory and related inflammatory cytokines (IL-1β, CCL4, IL-4, and IL-16). Following chronic treatment with the candidate drug, both the abnormal microglial morphology and the various plasma inflammatory markers in Ts65Dn mice returned to normal levels. These findings demonstrate that the drug effectively ameliorates hippocampal neuroinflammation and microglial pathological phenotypes in this Down syndrome mouse model.

Fig 2. Plasma inflammatory marker levels in the Ts65Dn mouse cohort. Quantifications of (A) IL-1β, (B) CCL4, (C) IL-16, and (D) IL-4. ^# P < 0.05 vs. vehicle group.

Why Choose Us?

• Scientific Expertise: Guided by a multidisciplinary team of veteran scientists with deep insights into rare disease biology and neurodevelopmental research.
• Integrated End-to-End Solutions: Seamlessly connecting custom model creation, vector design, in vitro validation, and in vivo safety/efficacy testing under one roof.
• Diverse & Multi-Species Model Portfolio: Offering custom Down syndrome animal models across mice and rats, spanning chromosomal translocations, gene edits, and humanized transgenic systems.
• Customized Study Designs: Tailoring every protocol to your target molecule's specific mechanism of action and strategic regulatory roadmap.

Contact Us

As a cutting-edge provider of preclinical research services, Protheragen offers a diverse portfolio of custom and validated animal models—including chromosomal translocation, transchromosomic, and humanized transgenic rodent systems—specifically tailored for Down syndrome research. These advanced platforms, combined with our end-to-end analytical capabilities, empower drug discovery teams to elucidate novel pathogenic mechanisms, identify translational biomarkers, and robustly evaluate therapeutic efficacy and safety. Contact our scientific experts today to discuss your study design.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Rare Disease Diagnostics Development
• Rare Disease Therapeutics Development
• Drug Repurposing Service
• Rare Disease Model Development Services
• Drug Safety Evaluation Services
• Pharmacokinetics Services